Bill Hoon Chang, M.D., Ph.D.
Dr. Chang's research focuses on understanding the biochemical mechanism responsible for resistance in refractory and relapse leukemias. Identifying these mechanisms will aid in the development of new therapies for these resistant diseases. Using RNA interference technologies he has been able to identify new biochemical targets for therapy. Dr. Chang's research continues in collaboration with the Children's Oncology Group to develop these targets for new therapies to these cancers.
"Comparison of methods to identify aberrant expression patterns in individual patients: Augmenting our toolkit for precision medicine,"
"Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening,"
"Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML,"
"TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia,"
"Abnormal developmental control of replication-timing domains in pediatric acute lymphoblastic leukemia,"